Odetiglucan
Odetiglucan is a differentiated, systemically administered therapeutic candidate that has been observed preclinically to play an important role in tumor immune interactions by modulating both the innate and adaptive immune system.
In preclinical studies and clinical testing it has been shown to have the potential to bind to a unique combination of receptors on innate immune cells, reprogramming the tumor microenvironment to drive a strong anti-cancer immune response.